A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking

• Noah J. Tubo ,

  Contributed equally to this work with: Noah J. Tubo, Marc A. Wurbel

  Affiliations Brigham and Women’s Hospital, Department of Dermatology, Boston, Massachusetts, United States of America, Harvard Medical School, Program in Biological and Biomedical Sciences, Boston, Massachusetts, United States of America

  ⨯
• Marc A. Wurbel ,

  Contributed equally to this work with: Noah J. Tubo, Marc A. Wurbel

  Affiliation Brigham and Women’s Hospital, Department of Dermatology, Boston, Massachusetts, United States of America

  ⨯
• Trevor T. Charvat,

  Affiliation ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California, United States of America

  ⨯
• Thomas J. Schall,

  Affiliation ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California, United States of America

  ⨯
• Matthew J. Walters,

  Affiliation ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California, United States of America

  ⨯
• James J. Campbell

  * E-mail: jcampbell@bwh.rics.harvard.edu

  Affiliations Brigham and Women’s Hospital, Department of Dermatology, Boston, Massachusetts, United States of America, Harvard Medical School, Departments of Dermatology and Pathology, Boston, Massachusetts, United States of America

  ⨯